middle.news
Alterity Strengthens ATH434 Data, Eyes FDA Phase 3 Nod with $49M Cash Buffer
10:28am on Friday 30th of January, 2026 AEDT
•
Biotechnology
Read Story
Alterity Strengthens ATH434 Data, Eyes FDA Phase 3 Nod with $49M Cash Buffer
10:28am on Friday 30th of January, 2026 AEDT
Key Points
Strengthened Phase 2 clinical data for ATH434 in MSA
Preparation underway for FDA End-of-Phase-2 meeting in mid-2026
Ongoing strategic partnering discussions to fund Phase 3
Board and executive leadership enhancements
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALTERITY THERAPEUTICS (ASX:ATH)
OPEN ARTICLE